| 产品名称： | KCL22-s |
|---|---|
| 商品货号： | TS214909 |
| Organism： | Homo sapiens, human |
| Tissue： | pleural effusion, bone marrow |
| Product Format： | frozen 1.0 mL |
| Morphology： | lymphoblast-like |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | chronic myeloid leukemia at blast crisis |
| Age： | 32 years |
| Gender： | female |
| Applications： | The paired KCL22-s and KCL22-r clones are useful cell line models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： |  |
| Comments： | BCR-ABL of the e13a2 fusion transcript type. |
| Complete Growth Medium： | The base medium for this cell line is RPMI-1640 (ATCC 30-2001). To make the complete medium add to 500 mL of the base medium:
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 105 cells/mL and maintain between 1.0 X 105 and 1.5 X 106 cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Complete culture medium + 10% DMSO (ATCC 4-X) |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% CO2
Temperature: 37°C |
| Volume： | 1.0 mL |
| STR Profile： | Amelogenin: X
CSF1PO: 11,12
D13S317: 8
D16S539:11,12
D5S818: 10,11
D7S820: 12
THO1: 7,9
TPOX: 8
vWA: 14 |
| Sterility Tests： | Bacteria and yeast: No growth Mycoplasma: No growth |
| Viral Testing： | Hepatitis B: None detected Cytomegalovirus: None detected Human immunodeficiency virus: None detected Epstein-Barr virus: None detected Human papillomavirus: None detected |
| Population Doubling Time： | 24 to 30 hours |
| Name of Depositor： | J Vaz de Melo, Dept of Hematology, Royal Adelaide Hospital, Australia |
| Year of Origin： | 1999 |
| References： | Tipping AJ, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 31(11):1073-80, 2003. PubMed: 14585372 Kubonishi I, et al. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1(2):105-17, 1983. PubMed: 3461189 Kubonishi I, et al. Two new Human Myeloid Cell Lines Derived from Acute Promyelo-cytic Leukemia and Chromic myelocytic leukemia. Gan 74: 319-322 1983. PubMed: 6576961 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | KCL22-s |
|---|---|
| 商品货号： | TS214909 |
| Organism： | Homo sapiens, human |
| Tissue： | pleural effusion, bone marrow |
| Product Format： | frozen 1.0 mL |
| Morphology： | lymphoblast-like |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | chronic myeloid leukemia at blast crisis |
| Age： | 32 years |
| Gender： | female |
| Applications： | The paired KCL22-s and KCL22-r clones are useful cell line models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： | |
| Comments： | BCR-ABL of the e13a2 fusion transcript type. |
| Complete Growth Medium： | The base medium for this cell line is RPMI-1640 (ATCC 30-2001). To make the complete medium add to 500 mL of the base medium:
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 105 cells/mL and maintain between 1.0 X 105 and 1.5 X 106 cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Complete culture medium + 10% DMSO (ATCC 4-X) |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% CO2
Temperature: 37°C |
| Volume： | 1.0 mL |
| STR Profile： | Amelogenin: X
CSF1PO: 11,12
D13S317: 8
D16S539:11,12
D5S818: 10,11
D7S820: 12
THO1: 7,9
TPOX: 8
vWA: 14 |
| Sterility Tests： | Bacteria and yeast: No growth Mycoplasma: No growth |
| Viral Testing： | Hepatitis B: None detected Cytomegalovirus: None detected Human immunodeficiency virus: None detected Epstein-Barr virus: None detected Human papillomavirus: None detected |
| Population Doubling Time： | 24 to 30 hours |
| Name of Depositor： | J Vaz de Melo, Dept of Hematology, Royal Adelaide Hospital, Australia |
| Year of Origin： | 1999 |
| References： | Tipping AJ, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 31(11):1073-80, 2003. PubMed: 14585372 Kubonishi I, et al. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1(2):105-17, 1983. PubMed: 3461189 Kubonishi I, et al. Two new Human Myeloid Cell Lines Derived from Acute Promyelo-cytic Leukemia and Chromic myelocytic leukemia. Gan 74: 319-322 1983. PubMed: 6576961 |
